NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Files An 8-K Results of Operations and Financial Condition
ITEM2.02
|
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. |
On February14, 2017, Neurocrine Biosciences, Inc. announced its
financial results for the fourth quarter and year ended
December31, 2016. The full text of the press release issued in
connection with the announcement is attached as Exhibit 99.1 to
this Current Report on Form 8-K.
In accordance with
General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K, including Exhibit99.1, shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act) or otherwise subject
to the liability of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
| ITEM9.01 | FINANCIAL STATEMENTS AND EXHIBITS. |
(d)
EXHIBITS.
|
Exhibit Number |
Description of Exhibit |
|
| 99.1 |
Press Release dated February14, 2017 |
About NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX)
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature. NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Recent Trading Information
NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) closed its last trading session down -0.61 at 41.53 with 1,275,170 shares trading hands.
